FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens

August 27, 2026 5:47 PM

Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found